Pfizer (PFE) is back in focus after two R&D milestones, a broader European indication for hemophilia drug HYMPAVZI and ...

(Reuters) -U.S. drugmaker Pfizer could work its connections within President Donald Trump's administration to try to thwart Novo Nordisk's surprise rival bid to acquire U.S. obesity biotech firm ...

As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the ...

Pfizer and its partners have granted Rigel Pharmaceuticals an exclusive license to commercialize VEPPANU (vepdegestrant), the ...

In my March article, "Why Pfizer Remains A Strong Buy In 2026", I mainly discussed Pfizer's Q4 earnings ( PFE) and the ...

Shares of German drug maker BioNTech SE rallied 24 per cent, while US-based Pfizer Inc. stock jumped over 14 per cent in pre-market trading on Monday after their COVID-19 vaccine candidate achieved ...

Pfizer (NYSE:PFE) has entered a new alliance with Sarah Cannon Research Institute to accelerate oncology clinical trials and ...

(Reuters) - U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age group and said it was a once-in-a-lifetime shot for now, excluding millions ...

The drug-pricing agreement Pfizer struck with the Trump administration in September could generate up to $280 million in annual savings for state Medicaid programs, according to an analysis published ...

Vaccinating a million adults ages 65 and above with a single RSV shot from Pfizer or GSK may prevent thousands of hospitalizations over two seasons of the virus, according to a CDC analysis. The ...